Standout Papers

Empagliflozin, Cardiovascular Outcomes, ... 2000 2026 2008 2017 7.8k
  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
    Bernard Zinman, Christoph Wanner et al. New England Journal of Medicine
  2. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
    Christoph Wanner, Silvio E. Inzucchi et al. New England Journal of Medicine
  3. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (2006)
    Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine
  4. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (2015)
    Jennifer B. Green, M. Angelyn Bethel et al. New England Journal of Medicine
  5. Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy (2000)
    John M. Lachin New England Journal of Medicine
  6. Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes (2006)
    Richard F. Hamman, Rena R. Wing et al. Diabetes Care
  7. Introduction to sample size determination and power analysis for clinical trials (1981)
    John M. Lachin Controlled Clinical Trials
  8. Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function (2009)
    Mark D. Pescovitz, Carla J. Greenbaum et al. New England Journal of Medicine
  9. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017)
    Silvio E. Inzucchi, Bernard Zinman et al. Diabetes Care
  10. Chenodiol (Chenodeoxycholic Acid) for Dissolution of Gallstones: The National Cooperative Gallstone Study (1981)
    Leslie J. Schoenfield, John M. Lachin et al. Annals of Internal Medicine
  11. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2017)
    Christoph Wanner, John M. Lachin et al. Circulation
  12. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality (2015)
    Trevor J. Orchard, David M. Nathan et al. JAMA

Immediate Impact

4 from Science/Nature 101 standout
Sub-graph 1 of 16

Citing Papers

Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
2023 Standout
Gliflozins in the Management of Cardiovascular Disease
2022 Standout
80 intermediate papers

Works of John M. Lachin being referenced

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
and 32 more

Author Peers

Author Last Decade Papers Cites
John M. Lachin 22038 2165 10391 8384 277 35.6k
Rury R. Holman 28999 398 9037 10634 347 39.3k
David M. Nathan 24422 164 8305 6745 161 38.5k
Juliana C.N. Chan 17123 186 5625 7584 830 37.4k
Peter H. Bennett 14536 62 5299 5684 288 34.6k
Hertzel C. Gerstein 25805 266 7930 8604 496 49.6k
William H. Herman 18393 116 5383 6767 404 35.1k
Santica M. Marcovina 11179 49 12070 3251 405 24.6k
Bruce Neal 15397 160 6754 5161 501 36.0k
William C. Knowler 21517 155 8108 10313 516 56.0k
K. G. M. M. Alberti 15637 29 4967 5577 237 32.5k

All Works

Loading papers...

Rankless by CCL
2026